Literature DB >> 8452230

Tannin-mediated attachment of avidin provides complement-resistant immunoerythrocytes that can be lysed in the presence of activator of complement.

V R Muzykantov1, M D Smirnov, A B Zaltzman, G P Samokhin.   

Abstract

It was shown previously that avidin attachment to biotinylated erythrocytes induces their lysis by homologous complement via the alternative pathway. This phenomenon hinders the use of avidin-coated immunoerythrocytes as carriers for drug targeting. In the present work we demonstrated that attachment of avidin to erythrocytes via the cross-linking agent tannin does not induce their lysis by complement. Tannization allows attachment of about 5 x 10(5) molecules of avidin per erythrocyte, which is comparable to the value obtained after treatment with biotin esters. In contrast to biotinylated avidin-coated erythrocytes, tannized avidin-coated erythrocytes were not lysed by complement. Tannization itself does not reduce the erythrocyte sensitivity to lysis by complement in the presence of activators of the complement (hemolytic antibody or activators of the alternative pathway). Therefore, the avidin-induced lysis by complement depends on the mode of avidin attachment to erythrocyte. Complement-resistant tannized erythrocytes coated with avidin bind biotinylated immunoglobulins (to 7 x 10(4) molecules per cell), suggesting that tannization might be used for the preparation of complement-resistant immunoerythrocytes.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8452230     DOI: 10.1006/abio.1993.1057

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  8 in total

Review 1.  Drug delivery by red blood cells: vascular carriers designed by mother nature.

Authors:  Vladimir R Muzykantov
Journal:  Expert Opin Drug Deliv       Date:  2010-04       Impact factor: 6.648

Review 2.  Red blood cells: The metamorphosis of a neglected carrier into the natural mothership for artificial nanocarriers.

Authors:  Patrick M Glassman; Elizabeth D Hood; Laura T Ferguson; Zongmin Zhao; Don L Siegel; Samir Mitragotri; Jacob S Brenner; Vladimir R Muzykantov
Journal:  Adv Drug Deliv Rev       Date:  2021-09-29       Impact factor: 15.470

3.  Cyclic arginine-glycine-aspartic acid-modified red blood cells for drug delivery: Synthesis and in vitro evaluation.

Authors:  Chen Wang; Min Wang; Yan Zhang; Hongxin Jia; Binbin Chen
Journal:  J Pharm Anal       Date:  2021-06-12

Review 4.  Delivery of drugs bound to erythrocytes: new avenues for an old intravascular carrier.

Authors:  Carlos H Villa; Daniel C Pan; Sergei Zaitsev; Douglas B Cines; Donald L Siegel; Vladimir R Muzykantov
Journal:  Ther Deliv       Date:  2015-07

5.  Enhanced complement susceptibility of avidin-biotin-treated human erythrocytes is a consequence of neutralization of the complement regulators CD59 and decay accelerating factor.

Authors:  A B Zaltzman; C W Van den Berg; V R Muzykantov; B P Morgan
Journal:  Biochem J       Date:  1995-05-01       Impact factor: 3.857

6.  Red Blood Cell Hitchhiking: A Novel Approach for Vascular Delivery of Nanocarriers.

Authors:  Jacob S Brenner; Samir Mitragotri; Vladimir R Muzykantov
Journal:  Annu Rev Biomed Eng       Date:  2021-03-31       Impact factor: 11.324

Review 7.  Red Blood Cell Membrane Processing for Biomedical Applications.

Authors:  Luigia Rossi; Alessandra Fraternale; Marzia Bianchi; Mauro Magnani
Journal:  Front Physiol       Date:  2019-08-20       Impact factor: 4.566

8.  Red Blood Cell Anchoring Enables Targeted Transduction and Re-Administration of AAV-Mediated Gene Therapy.

Authors:  Zongmin Zhao; Jayoung Kim; Vinny Chandran Suja; Neha Kapate; Yongsheng Gao; Junling Guo; Vladimir R Muzykantov; Samir Mitragotri
Journal:  Adv Sci (Weinh)       Date:  2022-07-03       Impact factor: 17.521

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.